As an experienced trader, my foremost priority is transparency on costs and risk. From my research and direct review of Mashreq’s offering, I find the overall trading cost structure around indices—like the US100—remains somewhat unclear and, frankly, cautious warning is warranted. Their published fee schedule thoroughly details account maintenance, cash handling, and a range of investment product commissions, particularly on equities and international exchanges. However, for speculative derivatives or CFDs on indices such as the US100, there is a noticeable lack of explicit information regarding spreads, overnight financing rates, or commission specifics. From my perspective and consistent with industry best practices, this sort of opacity can translate to unpredictable trading costs—especially important when trading highly leveraged markets such as indices. The absence of regulatory oversight compounds this concern; without direct regulation, there is simply no recourse or guarantee that costs and trade execution will align with advertised rates or prevailing industry standards. Given these factors, I would be highly reluctant to engage in index trading with Mashreq until there is fully transparent disclosure of the spread, overnight, and commission structures, as well as greater regulatory assurance. In my experience, these details are critical to protecting trading capital and ensuring a fair market environment.